Biodelivery Sci Intl (NASDAQ:BDSI):
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference.
The company is now up from yesterday’s close of 2.2.
BioDelivery Sciences International, Inc., launched on April 18, 2002, is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Business’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Business’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology..
The most current P/E ratio is 23.75 and market capitalization is 124.34M. In the latest earnings report the EPS was $0.09 with 55.88M shares outstanding.
Investors are a little more bullish on the company if you put credence in the change in short interest. The stock had a fall in short interest from September 29, 2017 to October 13, 2017 of -17.90%. Short shares fell 337,106 over that timeframe. The short-interest ratio decreased to 2.0 and the percentage of shorted shares is 0.03% as of October 13.
A few Wall Street investment firms have released ratings on the company recently. Piper Jaffray Companies updated coverage of BDSI with a rating of “Buy” and establishing a price target of $4.00. On October 13 analysts at HC Wainwright released research on BDSI stating a rating of “Buy” and a price target of $5.00.
Equity analyst Roth Capital issued a report on BDSI and giving a rating of “Buy” and price target of $5.00. On October 12, 2017 Cantor Fitzgerald released a research note on BDSI with a rating of “Buy” and setting a price target of $5.00.
Equity analyst HC Wainwright updated guidance on BDSI giving it an initial rating of “Buy”. August 20 investment analysts at Cantor Fitzgerald reiterated a “Overweight” rating on the stock.